- About Us
- Nano-Social Network
- Nano Consulting
- My Account
- Initial development focused on utilizing our nanoparticle elastic gel to improve topical product performance -
ULURU Inc. (OTC Bulletin Board: ULUR) today announced that it has commenced the development of a range of consumer pharmaceutical products under a development agreement signed with a major consumer pharmaceutical company.
The initial developments are focused on utilizing our nanoparticle
elastic adhesive gel, which offers the potential to significantly extend
the time that a flexible film stays in contact with the skin, to release
active compounds. Under the terms of the agreement ULURU will receive
payments for the development activities and has granted its development
partner a period of exclusivity to enter a potential licensing agreement.
Commenting on the agreement Kerry P. Gray, President and CEO of ULURU
Inc., stated "This is an important validation of our nanoparticle elastic
gel technology. Considerable interest has been expressed in this technology
by both consumer product and dermatology companies as the gel offers the
potential to extend the delivery of actives to the skin surface. Both the
gel technology and our erodible film technology give us the potential to
develop a range of differentiated consumer pharmaceutical products with a
significant period of patent protection. We continue to explore extensions
of our technology applications into the consumer pharmaceutical market as
this offers the potential to accelerate product revenue."
The nanoparticle elastic gel forms a transparent adhesive film that can
be spread on intact skin or superficial non-exudating wounds. The film can
be applied to irregular surfaces such as joints without impairing movement
and deliver active compounds for extended periods of time. Potential uses
of the elastic gel include treatment of acne, psoriasis, skin irritation,
scar management and cold sores.
About ULURU Inc.
ULURU Inc. is an emerging specialty pharmaceutical company focused on
the development of a portfolio of wound management, plastic surgery and
oral care products to provide patients and consumers improved clinical
outcomes through controlled delivery utilizing its innovative transmucosal
delivery system and Hydrogel Nanoparticle Aggregate technology. For further
information about ULURU Inc., please visit our website at
This press release contains certain statements that are forward-looking
within the meaning of Section 27a of the Securities Act of 1933, as
amended, including but not limited to statements made relating to potential
licensing arrangements, potential uses for our nanoparticle elastic gel
technology, interest expressed in this technology, and the potential for
accelerated product revenue. These statements are subject to numerous risks
and uncertainties, including but not limited to the risk factors detailed
in the Company's Annual Report on Form 10-KSB for the year ended December
31, 2006, Quarterly Report on Form 10-QSB for the quarter ended March 31,
2007 and other reports filed by us with the Securities and Exchange
For more information, please click here
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Strength of hair inspires new materials for body armor January 18th, 2017
GLOBALFOUNDRIES Expands Partner Program to Speed Time-to-Market of FDX™ Solutions: Increased support affirms FDXcelerator™ Program’s vital role in promoting broader deployment of GLOBALFOUNDRIES’ FDX™ portfolio December 15th, 2016
Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016